A multigene predictor of outcome in glioblastoma

Howard Colman, Li Zhang, Erik P. Sulman, J. Matthew McDonald, Nasrin Latif Shooshtari, Andreana Rivera, Sonya Popoff, Catherine L. Nutt, David N. Louis, J. Gregory Cairncross, Mark R. Gilbert, Heidi S. Phillips, Minesh P. Mehta, Arnab Chakravarti, Christopher E. Pelloski, Krishna Bhat, Burt G. Feuerstein, Robert Brian Jenkins, Ken Aldape

Research output: Contribution to journalArticle

242 Citations (Scopus)

Abstract

Only a subset of patients with newly diagnosed glioblastoma (GBM) exhibit a response to standard therapy. To date, a biomarker panel with predictive power to distinguish treatment sensitive from treatment refractory GBM tumors does not exist. An analysis was performed using GBM microarray data from 4 independent data sets. An examination of the genes consistently associated with patient outcome, revealed a consensus 38-gene survival set. Worse outcome was associated with increased expression of genes associated with mesenchymal differentiation and angiogenesis. Application to formalin fixed-paraffin embedded (FFPE) samples using realtime reverse-transcriptase polymerase chain reaction assays resulted in a 9-gene subset which appeared robust in these samples. This 9-gene set was then validated in an additional independent sample set. Multivariate analysis confirmed that the 9-gene set was an independent predictor of outcome after adjusting for clinical factors and methylation of the methylguanine methyltransferase promoter. The 9-gene profile was also positively associated with markers of glioma stem-like cells, including CD133 and nestin. In sum, a multigene predictor of outcome in glioblastoma was identified which appears applicable to routinely processed FFPE samples. The profile has potential clinical application both for optimization of therapy in GBM and for the identification of novel therapies targeting tumors refractory to standard therapy.

Original languageEnglish (US)
Pages (from-to)49-57
Number of pages9
JournalNeuro-Oncology
Volume12
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Glioblastoma
Genes
Paraffin
Formaldehyde
Therapeutics
Nestin
Methyltransferases
Reverse Transcriptase Polymerase Chain Reaction
Glioma
Methylation
Neoplasms
Stem Cells
Multivariate Analysis
Biomarkers
Gene Expression
Survival

Keywords

  • Biomarkers
  • Glioblastoma
  • MGMT promoter
  • Prognostic genes
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Colman, H., Zhang, L., Sulman, E. P., McDonald, J. M., Shooshtari, N. L., Rivera, A., ... Aldape, K. (2010). A multigene predictor of outcome in glioblastoma. Neuro-Oncology, 12(1), 49-57. https://doi.org/10.1093/neuonc/nop007

A multigene predictor of outcome in glioblastoma. / Colman, Howard; Zhang, Li; Sulman, Erik P.; McDonald, J. Matthew; Shooshtari, Nasrin Latif; Rivera, Andreana; Popoff, Sonya; Nutt, Catherine L.; Louis, David N.; Cairncross, J. Gregory; Gilbert, Mark R.; Phillips, Heidi S.; Mehta, Minesh P.; Chakravarti, Arnab; Pelloski, Christopher E.; Bhat, Krishna; Feuerstein, Burt G.; Jenkins, Robert Brian; Aldape, Ken.

In: Neuro-Oncology, Vol. 12, No. 1, 01.2010, p. 49-57.

Research output: Contribution to journalArticle

Colman, H, Zhang, L, Sulman, EP, McDonald, JM, Shooshtari, NL, Rivera, A, Popoff, S, Nutt, CL, Louis, DN, Cairncross, JG, Gilbert, MR, Phillips, HS, Mehta, MP, Chakravarti, A, Pelloski, CE, Bhat, K, Feuerstein, BG, Jenkins, RB & Aldape, K 2010, 'A multigene predictor of outcome in glioblastoma', Neuro-Oncology, vol. 12, no. 1, pp. 49-57. https://doi.org/10.1093/neuonc/nop007
Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A et al. A multigene predictor of outcome in glioblastoma. Neuro-Oncology. 2010 Jan;12(1):49-57. https://doi.org/10.1093/neuonc/nop007
Colman, Howard ; Zhang, Li ; Sulman, Erik P. ; McDonald, J. Matthew ; Shooshtari, Nasrin Latif ; Rivera, Andreana ; Popoff, Sonya ; Nutt, Catherine L. ; Louis, David N. ; Cairncross, J. Gregory ; Gilbert, Mark R. ; Phillips, Heidi S. ; Mehta, Minesh P. ; Chakravarti, Arnab ; Pelloski, Christopher E. ; Bhat, Krishna ; Feuerstein, Burt G. ; Jenkins, Robert Brian ; Aldape, Ken. / A multigene predictor of outcome in glioblastoma. In: Neuro-Oncology. 2010 ; Vol. 12, No. 1. pp. 49-57.
@article{aa4702ee104b4174aa603d43713330fd,
title = "A multigene predictor of outcome in glioblastoma",
abstract = "Only a subset of patients with newly diagnosed glioblastoma (GBM) exhibit a response to standard therapy. To date, a biomarker panel with predictive power to distinguish treatment sensitive from treatment refractory GBM tumors does not exist. An analysis was performed using GBM microarray data from 4 independent data sets. An examination of the genes consistently associated with patient outcome, revealed a consensus 38-gene survival set. Worse outcome was associated with increased expression of genes associated with mesenchymal differentiation and angiogenesis. Application to formalin fixed-paraffin embedded (FFPE) samples using realtime reverse-transcriptase polymerase chain reaction assays resulted in a 9-gene subset which appeared robust in these samples. This 9-gene set was then validated in an additional independent sample set. Multivariate analysis confirmed that the 9-gene set was an independent predictor of outcome after adjusting for clinical factors and methylation of the methylguanine methyltransferase promoter. The 9-gene profile was also positively associated with markers of glioma stem-like cells, including CD133 and nestin. In sum, a multigene predictor of outcome in glioblastoma was identified which appears applicable to routinely processed FFPE samples. The profile has potential clinical application both for optimization of therapy in GBM and for the identification of novel therapies targeting tumors refractory to standard therapy.",
keywords = "Biomarkers, Glioblastoma, MGMT promoter, Prognostic genes, Temozolomide",
author = "Howard Colman and Li Zhang and Sulman, {Erik P.} and McDonald, {J. Matthew} and Shooshtari, {Nasrin Latif} and Andreana Rivera and Sonya Popoff and Nutt, {Catherine L.} and Louis, {David N.} and Cairncross, {J. Gregory} and Gilbert, {Mark R.} and Phillips, {Heidi S.} and Mehta, {Minesh P.} and Arnab Chakravarti and Pelloski, {Christopher E.} and Krishna Bhat and Feuerstein, {Burt G.} and Jenkins, {Robert Brian} and Ken Aldape",
year = "2010",
month = "1",
doi = "10.1093/neuonc/nop007",
language = "English (US)",
volume = "12",
pages = "49--57",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - A multigene predictor of outcome in glioblastoma

AU - Colman, Howard

AU - Zhang, Li

AU - Sulman, Erik P.

AU - McDonald, J. Matthew

AU - Shooshtari, Nasrin Latif

AU - Rivera, Andreana

AU - Popoff, Sonya

AU - Nutt, Catherine L.

AU - Louis, David N.

AU - Cairncross, J. Gregory

AU - Gilbert, Mark R.

AU - Phillips, Heidi S.

AU - Mehta, Minesh P.

AU - Chakravarti, Arnab

AU - Pelloski, Christopher E.

AU - Bhat, Krishna

AU - Feuerstein, Burt G.

AU - Jenkins, Robert Brian

AU - Aldape, Ken

PY - 2010/1

Y1 - 2010/1

N2 - Only a subset of patients with newly diagnosed glioblastoma (GBM) exhibit a response to standard therapy. To date, a biomarker panel with predictive power to distinguish treatment sensitive from treatment refractory GBM tumors does not exist. An analysis was performed using GBM microarray data from 4 independent data sets. An examination of the genes consistently associated with patient outcome, revealed a consensus 38-gene survival set. Worse outcome was associated with increased expression of genes associated with mesenchymal differentiation and angiogenesis. Application to formalin fixed-paraffin embedded (FFPE) samples using realtime reverse-transcriptase polymerase chain reaction assays resulted in a 9-gene subset which appeared robust in these samples. This 9-gene set was then validated in an additional independent sample set. Multivariate analysis confirmed that the 9-gene set was an independent predictor of outcome after adjusting for clinical factors and methylation of the methylguanine methyltransferase promoter. The 9-gene profile was also positively associated with markers of glioma stem-like cells, including CD133 and nestin. In sum, a multigene predictor of outcome in glioblastoma was identified which appears applicable to routinely processed FFPE samples. The profile has potential clinical application both for optimization of therapy in GBM and for the identification of novel therapies targeting tumors refractory to standard therapy.

AB - Only a subset of patients with newly diagnosed glioblastoma (GBM) exhibit a response to standard therapy. To date, a biomarker panel with predictive power to distinguish treatment sensitive from treatment refractory GBM tumors does not exist. An analysis was performed using GBM microarray data from 4 independent data sets. An examination of the genes consistently associated with patient outcome, revealed a consensus 38-gene survival set. Worse outcome was associated with increased expression of genes associated with mesenchymal differentiation and angiogenesis. Application to formalin fixed-paraffin embedded (FFPE) samples using realtime reverse-transcriptase polymerase chain reaction assays resulted in a 9-gene subset which appeared robust in these samples. This 9-gene set was then validated in an additional independent sample set. Multivariate analysis confirmed that the 9-gene set was an independent predictor of outcome after adjusting for clinical factors and methylation of the methylguanine methyltransferase promoter. The 9-gene profile was also positively associated with markers of glioma stem-like cells, including CD133 and nestin. In sum, a multigene predictor of outcome in glioblastoma was identified which appears applicable to routinely processed FFPE samples. The profile has potential clinical application both for optimization of therapy in GBM and for the identification of novel therapies targeting tumors refractory to standard therapy.

KW - Biomarkers

KW - Glioblastoma

KW - MGMT promoter

KW - Prognostic genes

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=75749115909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749115909&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nop007

DO - 10.1093/neuonc/nop007

M3 - Article

C2 - 20150367

AN - SCOPUS:75749115909

VL - 12

SP - 49

EP - 57

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 1

ER -